FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379339089> ?p ?o ?g. }

• W4379339089 endingPage "7545" @default.
• W4379339089 startingPage "7545" @default.
• W4379339089 abstract "7545 Background: In an early-phase study, the combination of zanubrutinib plus obinutuzumab (ZO) was well tolerated and associated with an early signal of efficacy in patients (pts) with follicular lymphoma (FL) (Tam et al. Blood Adv 2020). ROSEWOOD (NCT03332017) is a phase 2, randomized study designed to assess efficacy and safety of ZO vs obinutuzumab (O) in pts with relapsed/refractory (R/R) FL. Here, we present an updated analysis with a median follow-up of 20.2 mo. Methods: Pts with R/R FL (grade 1–3a) who received ≥2 lines of therapy including an anti-CD20 antibody and alkylating agent were randomized 2:1 to receive ZO or O. Zanubrutinib was given at 160 mg twice daily until progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) by independent central review. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and safety. Results: A total of 217 pts were randomized (145 for ZO; 72 for O). Median age was 64 years. Of the 217 pts, 114 (52.5%) had a high Follicular Lymphoma International Prognostic Index (FLIPI) score at screening and 123 (56.7%) pts had high tumor burden criteria according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria. Median number of prior lines of therapy was 3 (range, 2–11). A total of 114 (52.5%) pts were refractory to rituximab; 214 (98.6%) pts received prior immunochemotherapy. Prior exposure to anticancer drugs included anthracyclines (80.6%), cyclophosphamide (94.0%), and bendamustine (54.8%). ORR was 69.0% (ZO) vs 45.8% (O) ( P = 0.0012). Complete response rate was 39.3% (ZO) vs 19.4% (O); 18-mo DOR rate was 69.3% (ZO) vs 41.9% (O); median PFS was 28.0 mo (ZO) vs 10.4 mo (O) (hazard ratio [HR], 0.50 [95% CI: 0.33, 0.75]; P = 0.0007). Median TTNT was not evaluable for ZO and 12.2 mo for O (HR, 0.34 [95% CI: 0.22, 0.52]; P < 0.0001). Estimated OS rate at 24 mo was 77.3% (ZO) and 71.4% (O), with median OS not reached in either arm. Nonhematologic treatment-emergent adverse events of any grade that occurred more frequently for ZO vs O ( > 5% difference) were petechiae (6.3% vs 0%) and herpes zoster infection (6.3% vs 0%); in contrast, pyrexia (13.3% vs 19.7%) and infusion-related reaction (2.8% vs 9.9%) occurred more frequently in pts on O. When adjusted for duration of treatment exposure, incidences of infection and cytopenia were similar, and incidence of all grades of hemorrhage was 2.4 (ZO) vs 1.3 (O) persons per 100 person-months. Two pts in each treatment group reported major hemorrhage. Incidences of atrial fibrillation and hypertension were low and similar in both treatment arms. Conclusions: ZO demonstrated meaningful activity and a manageable safety profile in pts with heavily pretreated R/R FL, representing a potential novel therapy. Clinical trial information: NCT03332017 ." @default.
• W4379339089 created "2023-06-05" @default.
• W4379339089 creator A5000991854 @default.
• W4379339089 creator A5004358361 @default.
• W4379339089 creator A5006621752 @default.
• W4379339089 creator A5014849816 @default.
• W4379339089 creator A5014942120 @default.
• W4379339089 creator A5017502227 @default.
• W4379339089 creator A5023044472 @default.
• W4379339089 creator A5029774831 @default.
• W4379339089 creator A5035561437 @default.
• W4379339089 creator A5049333477 @default.
• W4379339089 creator A5054654885 @default.
• W4379339089 creator A5063675719 @default.
• W4379339089 creator A5068452218 @default.
• W4379339089 creator A5069456938 @default.
• W4379339089 creator A5069918654 @default.
• W4379339089 creator A5074729432 @default.
• W4379339089 creator A5082805908 @default.
• W4379339089 creator A5082892912 @default.
• W4379339089 creator A5090751806 @default.
• W4379339089 creator A5091882595 @default.
• W4379339089 date "2023-06-01" @default.
• W4379339089 modified "2023-10-16" @default.
• W4379339089 title "Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study." @default.
• W4379339089 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7545" @default.
• W4379339089 hasPublicationYear "2023" @default.
• W4379339089 type Work @default.
• W4379339089 citedByCount "0" @default.
• W4379339089 crossrefType "journal-article" @default.
• W4379339089 hasAuthorship W4379339089A5000991854 @default.
• W4379339089 hasAuthorship W4379339089A5004358361 @default.
• W4379339089 hasAuthorship W4379339089A5006621752 @default.
• W4379339089 hasAuthorship W4379339089A5014849816 @default.
• W4379339089 hasAuthorship W4379339089A5014942120 @default.
• W4379339089 hasAuthorship W4379339089A5017502227 @default.
• W4379339089 hasAuthorship W4379339089A5023044472 @default.
• W4379339089 hasAuthorship W4379339089A5029774831 @default.
• W4379339089 hasAuthorship W4379339089A5035561437 @default.
• W4379339089 hasAuthorship W4379339089A5049333477 @default.
• W4379339089 hasAuthorship W4379339089A5054654885 @default.
• W4379339089 hasAuthorship W4379339089A5063675719 @default.
• W4379339089 hasAuthorship W4379339089A5068452218 @default.
• W4379339089 hasAuthorship W4379339089A5069456938 @default.
• W4379339089 hasAuthorship W4379339089A5069918654 @default.
• W4379339089 hasAuthorship W4379339089A5074729432 @default.
• W4379339089 hasAuthorship W4379339089A5082805908 @default.
• W4379339089 hasAuthorship W4379339089A5082892912 @default.
• W4379339089 hasAuthorship W4379339089A5090751806 @default.
• W4379339089 hasAuthorship W4379339089A5091882595 @default.
• W4379339089 hasConcept C121332964 @default.
• W4379339089 hasConcept C126322002 @default.
• W4379339089 hasConcept C141071460 @default.
• W4379339089 hasConcept C142424586 @default.
• W4379339089 hasConcept C143998085 @default.
• W4379339089 hasConcept C168563851 @default.
• W4379339089 hasConcept C203092338 @default.
• W4379339089 hasConcept C2776694085 @default.
• W4379339089 hasConcept C2777058707 @default.
• W4379339089 hasConcept C2777063308 @default.
• W4379339089 hasConcept C2777607594 @default.
• W4379339089 hasConcept C2778476033 @default.
• W4379339089 hasConcept C2779338263 @default.
• W4379339089 hasConcept C2780653079 @default.
• W4379339089 hasConcept C2780739268 @default.
• W4379339089 hasConcept C2780775027 @default.
• W4379339089 hasConcept C71924100 @default.
• W4379339089 hasConcept C87355193 @default.
• W4379339089 hasConcept C90924648 @default.
• W4379339089 hasConceptScore W4379339089C121332964 @default.
• W4379339089 hasConceptScore W4379339089C126322002 @default.
• W4379339089 hasConceptScore W4379339089C141071460 @default.
• W4379339089 hasConceptScore W4379339089C142424586 @default.
• W4379339089 hasConceptScore W4379339089C143998085 @default.
• W4379339089 hasConceptScore W4379339089C168563851 @default.
• W4379339089 hasConceptScore W4379339089C203092338 @default.
• W4379339089 hasConceptScore W4379339089C2776694085 @default.
• W4379339089 hasConceptScore W4379339089C2777058707 @default.
• W4379339089 hasConceptScore W4379339089C2777063308 @default.
• W4379339089 hasConceptScore W4379339089C2777607594 @default.
• W4379339089 hasConceptScore W4379339089C2778476033 @default.
• W4379339089 hasConceptScore W4379339089C2779338263 @default.
• W4379339089 hasConceptScore W4379339089C2780653079 @default.
• W4379339089 hasConceptScore W4379339089C2780739268 @default.
• W4379339089 hasConceptScore W4379339089C2780775027 @default.
• W4379339089 hasConceptScore W4379339089C71924100 @default.
• W4379339089 hasConceptScore W4379339089C87355193 @default.
• W4379339089 hasConceptScore W4379339089C90924648 @default.
• W4379339089 hasFunder F4320317235 @default.
• W4379339089 hasIssue "16_suppl" @default.
• W4379339089 hasLocation W43793390891 @default.
• W4379339089 hasOpenAccess W4379339089 @default.
• W4379339089 hasPrimaryLocation W43793390891 @default.
• W4379339089 hasRelatedWork W2073392337 @default.
• W4379339089 hasRelatedWork W2092717964 @default.
• W4379339089 hasRelatedWork W2766754685 @default.
• W4379339089 hasRelatedWork W2781857495 @default.
• W4379339089 hasRelatedWork W2784462793 @default.

• next